Trial of Nivolumab With Chemotherapy as Neoadjuvant Treatment in Inflammatory Breast Cancer (IBC)

Condition:   Breast Cancer Interventions:   Drug: Nivolumab 360 mg+ paclitaxel 80 mg/m2;   Drug: Doxorubicin 60 mg/m2+Cyclophosphamide 600 mg/m2;   Drug: Nivolumab 360 mg+ Docetaxel* 75 mg/m2 +Trastuzumab 8 mg/kg +Pertuzumab 840 mg;   Drug: Doxorubicin 60 mg/m2 +Cyclophosphamide 600 mg/m2 Sponsor:   New York University School of Medicine Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials